Matthias Wiedenfels - STADA Arzneimittel Executive
Executive
Dr. Matthias Wiedenfels is Chief Executive Officer Member of the Executive Board and Chief Business Development and Central Services Officer at STADA Arzneimittel AG effective June 5 2016. He was Member of the Executive Board Chief Business Development and Central Services Officer at the Company from May 2013 to June 5 2016 He is responsible for Business Development Portfolio Management Human Resources Legal IPPatents Compliance Risk Management as well as for Quality Assurance and Quality Control at the Company. since 2016.
| Age | 43 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 49 6101 603 0 |
| Web | http://www.stada.de |
STADA Arzneimittel Management Efficiency
The company has return on total asset (ROA) of 6.39 % which means that it generated a profit of $6.39 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 22.55 %, meaning that it generated $22.55 on every $100 dollars invested by stockholders. STADA Arzneimittel's management efficiency ratios could be used to measure how well STADA Arzneimittel manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 1.73 B in total debt with debt to equity ratio (D/E) of 2.58, implying the company greatly relies on financing operations through barrowing. STADA Arzneimittel has a current ratio of 1.46, which is within standard range for the sector. Debt can assist STADA Arzneimittel until it has trouble settling it off, either with new capital or with free cash flow. So, STADA Arzneimittel's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like STADA Arzneimittel sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for STADA to invest in growth at high rates of return. When we think about STADA Arzneimittel's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Terrence Schneider | Digi International | 58 | |
| Joaquin Cruz | Grupo Televisa SAB | N/A | |
| Jon Richards | Diamond Offshore Drilling | 50 | |
| John Dalsvag | KNOT Offshore Partners | N/A | |
| Kevin Bordosky | Diamond Offshore Drilling | N/A | |
| Brian Kirkendall | Digi International | N/A | |
| Kane Liddelow | Diamond Offshore Drilling | N/A | |
| Beth Gordon | Diamond Offshore Drilling | 63 | |
| Carlos Margain | Grupo Televisa SAB | 50 | |
| Juan Newman | Grupo Televisa SAB | N/A | |
| Giovanni Rier | Grupo Televisa SAB | N/A | |
| Brian Ballenger | Digi International | N/A | |
| Isaac Lee | Grupo Televisa SAB | N/A | |
| Tom Caden | Digi International | N/A | |
| Richard Male | Diamond Offshore Drilling | N/A | |
| Rodrigo Villanueva | Grupo Televisa SAB | N/A | |
| Samir Ali | Diamond Offshore Drilling | N/A | |
| Ricardo Yanez | Grupo Televisa SAB | 51 | |
| Joel Vengco | Digi International | N/A | |
| Suzy Arrabito | Reservoir Media | N/A | |
| Justin Schmid | Digi International | N/A | |
Management Performance
| Return On Equity | 22.55 | |||
| Return On Asset | 6.39 |
STADA Arzneimittel Leadership Team
Elected by the shareholders, the STADA Arzneimittel's board of directors comprises two types of representatives: STADA Arzneimittel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STADA. The board's role is to monitor STADA Arzneimittel's management team and ensure that shareholders' interests are well served. STADA Arzneimittel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STADA Arzneimittel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carl Oetker, Member of the Supervisory Board | ||
| JanNicolas Garbe, Member of the Supervisory Board | ||
| Dieter Koch, Member of the Supervisory Board | ||
| Eckhard Brueggemann, Member of the Supervisory Board | ||
| Mark Keatley, CFO, Member of the Executive Board | ||
| Ralph Grobecker, Managing Director of OTC segment | ||
| Martin Abend, Chairman of the Supervisory Board | ||
| Matthias Wiedenfels, Chief Bus. Devel. and Central Services Officer and Member of Executive Board | ||
| Arnold Hertzsch, Member of the Supervisory Board | ||
| Halil Duru, Member of the Supervisory Board | ||
| Tina Mueller, Member of the Supervisory Board | ||
| Engelbert Willink, Chairman of the Executive Board, CEO | ||
| Barthold Piening, Chief Technical Operations Officer, Member of the Executive Board | ||
| Steffen Wagner, Member of the Management Board, Head of Europe | ||
| Helmut Kraft, CFO and Member of Executive Board | ||
| Ute Pantke, Member of the Supervisory Board | ||
| Carsten Cron, Member of the Management Board, Head Emerging Markets | ||
| Frank Seiler, IR Contact Officer | ||
| Hartmut Retzlaff, Chairman of The Executive Board | ||
| Bernhard Duettmann, CFO | ||
| Miguel Pagan, Member of the Executive Board | ||
| Claudio Albrecht, Chairman of the Executive Board, CEO | ||
| Michael Siefke, Member of the Supervisory Board | ||
| Leslie Iltgen, Vice President Investor Relations | ||
| Eric Cornut, Member of the Supervisory Board | ||
| Peter Goldschmidt, Chairman of the Executive Board | ||
| Robert Knerr, Member of the Management Board, Head of Business Development | ||
| Jens Steegers, Member of the Supervisory Board | ||
| Birgit Kudlek, Member of the Supervisory Board | ||
| Guenter Au, Chairman of the Supervisory Board | ||
| Constantin Meyer, Member of the Supervisory Board | ||
| Rolf Hoffmann, Member of the Supervisory Board | ||
| Markus Metzger, Director of Investor Relations | ||
| Benjamin Kunstler, Member of the Supervisory Board | ||
| Gunnar Riemann, Member of the Supervisory Board | ||
| Bruno Schick, Member of the Supervisory Board |
STADA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is STADA Arzneimittel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 22.55 | |||
| Return On Asset | 6.39 | |||
| Profit Margin | 9.00 % | |||
| Current Valuation | 6.87 B | |||
| Shares Outstanding | 62.26 M | |||
| Shares Owned By Institutions | 0.30 % | |||
| Price To Earning | 22.46 X | |||
| Price To Book | 4.54 X | |||
| Price To Sales | 2.11 X | |||
| Revenue | 2.69 B |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the STADA Arzneimittel information on this page should be used as a complementary analysis to other STADA Arzneimittel's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in STADA OTC Stock
If you are still planning to invest in STADA Arzneimittel check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the STADA Arzneimittel's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |